Fig. 4: Progression-free survival (a) and overall survival (b) by cetuximab-free interval. | British Journal of Cancer

Fig. 4: Progression-free survival (a) and overall survival (b) by cetuximab-free interval.

From: Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08

Fig. 4

a The median progression-free survival is 4.6 months in the long CFI group and 2.1 months in the short CFI group (hazard ratio, 0.40; 95% CI, 0.18–0.86; p = 0.020). b The median overall survival is 14.6 months in the long CFI group and 6.3 months in the short CFI group (hazard ratio, 0.31; 95% CI, 0.13–0.74; p = 0.008). CFI cetuximab-free interval, CI confidence interval.

Back to article page